These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 6108445

  • 41. Immunoprophylaxis of Pseudomonas aeruginosa.
    Young LS, Armstrong D, Markley K.
    Ann Intern Med; 1971 Jun; 74(6):1012-3. PubMed ID: 4996343
    [No Abstract] [Full Text] [Related]

  • 42. [Pseudomonas immunoglobulin prophylaxis in patients with burn injuries].
    Stuttmann R, Petrovici V, Hartert M.
    Infection; 1987 Jun; 15 Suppl 2():S71-5. PubMed ID: 3112025
    [Abstract] [Full Text] [Related]

  • 43. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model.
    Felts AG, Giridhar G, Grainger DW, Slunt JB.
    Burns; 1999 Aug; 25(5):415-23. PubMed ID: 10439150
    [Abstract] [Full Text] [Related]

  • 44. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
    Yang F, Gu J, Yang L, Gao C, Jing H, Wang Y, Zeng H, Zou Q, Lv F, Zhang J.
    Sci Rep; 2017 Jun 21; 7(1):3957. PubMed ID: 28638106
    [Abstract] [Full Text] [Related]

  • 45. Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.
    Mansouri E, Blome-Eberwein S, Gabelsberger J, Germann G, von Specht BU.
    FEMS Immunol Med Microbiol; 2003 Jul 15; 37(2-3):161-6. PubMed ID: 12832120
    [Abstract] [Full Text] [Related]

  • 46. Early protection by vaccines against Pseudomonas aeruginosa colonizing burns.
    Jones RJ, Lowbury EJ.
    Br J Exp Pathol; 1972 Dec 15; 53(6):659-64. PubMed ID: 4630411
    [Abstract] [Full Text] [Related]

  • 47. A new Pseudomonas vaccine: preliminary trial on human volunteers.
    Jones RJ, Roe EA, Lowbury EJ, Miler JJ, Spilsbury JF.
    J Hyg (Lond); 1976 Jun 15; 76(3):429-39. PubMed ID: 819576
    [Abstract] [Full Text] [Related]

  • 48. [Experimental basis for the combined use of tobramycin and immune preparations for treating acute Pseudomonas aeruginosa infections].
    Minukhin VV, Tsyganenko VIa.
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Aug 15; (8):42-5. PubMed ID: 3094301
    [Abstract] [Full Text] [Related]

  • 49. [Pyocyanic infection in burned patients. Immunitary protection].
    Moyen EN, Lesage D, Romano P.
    Nouv Presse Med; 1972 Apr 01; 1(14):947-50. PubMed ID: 4623061
    [No Abstract] [Full Text] [Related]

  • 50. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
    Moroz AF, Kharitonova AM, Chanturiia TsK.
    Antibiotiki; 1983 May 01; 28(5):341-5. PubMed ID: 6410985
    [Abstract] [Full Text] [Related]

  • 51. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ, Roe EA.
    Br J Exp Pathol; 1975 Feb 01; 56(1):34-43. PubMed ID: 812544
    [Abstract] [Full Text] [Related]

  • 52. Pseudomonas aeruginosa: prevention better than cure?
    Mellor JA, Miler JJ.
    Dev Biol Stand; 1979 Feb 01; 43():53-9. PubMed ID: 118071
    [Abstract] [Full Text] [Related]

  • 53. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results.
    Langford DT, Hiller J.
    Arch Dis Child; 1984 Dec 01; 59(12):1131-4. PubMed ID: 6441523
    [Abstract] [Full Text] [Related]

  • 54. Passive immunization against Pseudomonas aeruginosa recombinant PilA in a murine burn wound model.
    Mousavi M, Behrouz B, Irajian G, Mahdavi M, Korpi F, Motamedifar M.
    Microb Pathog; 2016 Dec 01; 101():83-88. PubMed ID: 27836762
    [Abstract] [Full Text] [Related]

  • 55. The successful control of burn wound sepsis.
    Lindberg RB, Moncrief JA, Switzer WE, Order SE, Mills W.
    J Trauma; 1965 Sep 01; 5(5):601-16. PubMed ID: 5318146
    [No Abstract] [Full Text] [Related]

  • 56. [Experimental vaccinal prophylaxis of Pseudomonas aeruginosa burn sepsis].
    Bandman OA, Stanislavskiĭ ES, Kholodkova EV, Ivanova TV, Salov VF.
    Zh Mikrobiol Epidemiol Immunobiol; 1989 Jul 01; (7):59-62. PubMed ID: 2510430
    [Abstract] [Full Text] [Related]

  • 57. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U, Mansouri E, von Specht BU.
    Vaccine; 2004 Feb 17; 22(7):840-7. PubMed ID: 15040936
    [Abstract] [Full Text] [Related]

  • 58. Epidemiology of infections with Pseudomonas aeruginosa in burn patients: the role of hydrotherapy.
    Tredget EE, Shankowsky HA, Joffe AM, Inkson TI, Volpel K, Paranchych W, Kibsey PC, Alton JD, Burke JF.
    Clin Infect Dis; 1992 Dec 17; 15(6):941-9. PubMed ID: 1457665
    [Abstract] [Full Text] [Related]

  • 59. Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis.
    Zuercher AW, Horn MP, Que JU, Ruedeberg A, Schoeni MH, Schaad UB, Marcus P, Lang AB.
    FEMS Immunol Med Microbiol; 2006 Jul 17; 47(2):302-8. PubMed ID: 16831219
    [Abstract] [Full Text] [Related]

  • 60. Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species.
    Cryz SJ, Fürer E, Sadoff JC, Fredeking T, Que JU, Cross AS.
    J Infect Dis; 1991 May 17; 163(5):1055-61. PubMed ID: 1902245
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.